Shanghai Cell Therapy Group, founded in 2013, positions itself as a platform company that closes the loop across new‑drug R&D, tumor clinical treatment and cell preservation services. Its core products and clinical pipeline include the non‑viral vector CD19 CAR‑T injection BZ019, which the company says was the first non‑viral CAR‑T product in China to enter clinical trials; related clinical results were accepted by the Journal for ImmunoTherapy of Cancer. The group has invested in clinical and infrastructure assets, including an 800 million RMB investment to establish the Shanghai Mengchao Oncology Hospital as a Shanghai University‑affiliated hospital and insurance‑covered clinical center. A new international cell production center (1.6万平方米) was scheduled for completion in April 2021 with an announced capacity to prepare CAR‑T cells for up to 20,000 patients annually; additional talent and campus facilities (including a Nobel center and staff apartments) were planned for 2021 completion. The company reports extensive IP and expert engagement, with 217 patents, 193 invention patents, 167 trademarks, collaborations with 32 Nobel laureates and five domestic/international academy members, and partnerships with institutions such as USC and Shanghai University. The company has expanded regionally with multiple provincial cell therapy groups established in 2019–2020. Shanghai Cell Therapy Group focuses on R&D of cellular immunotherapy technologies and develops novel cell therapies while providing large‑scale cell banking and cryopreservation services. The company is building clinical capacity, including the soon‑to‑open Shanghai Wu Mengchao Cancer Hospital, and operates clinical testing that conforms to CFDA, USFDA and JCI standards. It plans a 200‑room production facility, a 3,000 m2 quality control center, and a cell preservation warehouse with capacity for 30 million human samples. Shanghai Cell Therapy Group has pursued an active IP program, applying for 117 patents (25 PCT) with 21 approvals including two U.S. patents. Thirty of its cellular immunotherapy technologies have received clinical ethical approval and 20 have been registered with the National Clinical Trial Institute. The company cites policy support from Shanghai municipal plans and is based in the Jiading medical‑industry district.

Total raised

$211M

Funding rounds

2

Latest round

Series D

Latest activity

Mar 2021